ホーム Open-label trial and randomized, double-blind, placebo-controlled, crossover trial of hydrogen-enriched water for mitochondrial and inflammatory myopathies.
Ito M*, Ibi T, Sahashi K, Ichihara M, Ito M, Ohno K.
*Division of Neurogenetics, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, 65 Tsurumai, Showa-ku, Nagoya 466-8550, Japan.
前の記事Dose-specific effects of tumor necrosis factor alpha on osteogenic differentiation of mesenchymal stem cells.
次の記事Mitochondria-targeted antioxidants for treatment of Parkinson’s disease: preclinical and clinical outcomes.